Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.70 |
| ▸ | NPY4R | P50391 | 9/20 | 0.59 |
| ▸ | NPY1R | P25929 | 6/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.59 |
| ▸ | NPY2R | P49146 | 4/20 | 0.59 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.58 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385132 | 0.92 | TFPI (0.63) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30436216 | 0.89 | TFPI (0.79) | TFPIVIPR2VIPR1 | |
| Mmi-0100 SCHEMBL29380469 | 0.88 | TFPI (0.65) | TFPINPY4RNPY1RNPY5RNPY2R | |
| Misgurin SCHEMBL29509599 | 0.88 | TFPI (0.72) | TFPIVIPR2VIPR1 | |
| SCHEMBL29770069 | 0.88 | TFPI (0.63) | TFPIIL23R | |
| SCHEMBL29551264 | 0.88 | TFPI (0.71) | TFPIVIPR2VIPR1 | |
| SCHEMBL29851163 | 0.88 | TFPI (0.71) | TFPIVIPR2VIPR1 | |
| SCHEMBL10535233 | 0.88 | TFPI (0.62) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL10535214 | 0.88 | TFPI (0.62) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30512596 | 0.88 | NPY4R (0.67) | TFPINPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673119-A1 | PROCESS FOR PREPARATION OF DUAL GIP/GLP-1 PEPTIDES HAVING CONTROLLED PARTICLE SIZE | Assia Chemical Industries Ltd. (IL) | 2026-01-07 | — | — | EP | claimed |
| WO-2025133045-A1 | FERMENTATION PROCESS | NOVO NORDISK A/S (DK) | 2025-06-26 | — | — | WO | claimed |
| WO-2025133729-A1 | PROCESS FOR PREPARATION OF GLP-1 PEPTIDES AND DUAL GLP-1/GIP PEPTIDES HAVING CONTROLLED PARTICLE SIZE | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-06-26 | — | — | WO | claimed |
| WO-2024180512-A1 | PROCESS FOR PREPARATION OF DUAL GIP/GLP-1 PEPTIDES HAVING CONTROLLED PARTICLE SIZE | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2024-09-06 | — | — | WO | claimed |
| EP-4713019-A2 | CPG CONJUGATES AND METHODS OF USE | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2026046202-A1 | USE OF GLP-1/GIP PEPTIDE OR PHARMACEUTICAL COMPOSITION CONTAINING SAME | 博瑞生物医药（苏州）股份有限公司 | 2026-03-05 | — | — | WO | disclosed |
| WO-2026046202-A1 | USE OF GLP-1/GIP PEPTIDE OR PHARMACEUTICAL COMPOSITION CONTAINING SAME | 博瑞生物医药（苏州）股份有限公司 | 2026-03-05 | — | — | WO | disclosed |
| EP-4701649-A1 | TREATMENT OF DIABETES MELLITUS | Carmot Therapeutics Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4673119-A1 | PROCESS FOR PREPARATION OF DUAL GIP/GLP-1 PEPTIDES HAVING CONTROLLED PARTICLE SIZE | Assia Chemical Industries Ltd. (IL) | 2026-01-07 | — | — | EP | disclosed |
| US-12492236-B2 | Fusion proteins for the treatment of cardiometabolic diseases | SHATTUCK LABS, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025133045-A1 | FERMENTATION PROCESS | NOVO NORDISK A/S (DK) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025133729-A1 | PROCESS FOR PREPARATION OF GLP-1 PEPTIDES AND DUAL GLP-1/GIP PEPTIDES HAVING CONTROLLED PARTICLE SIZE | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-06-26 | — | — | WO | disclosed |
| WO-2023121699-A1 | CYCLIC PEPTIDE FOR CANCER IMMUNOTHERAPY | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2023-06-29 | — | — | WO | disclosed |
| US-11590237-B2 | Pharmaceutical formulation comprising incretin-insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11572399-B2 | Long-acting GIP peptide analogues | UNIVERSITY OF COPENHAGEN (DK) | 2023-02-07 | — | — | US | disclosed |
| US-11555057-B2 | Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-17 | — | — | US | disclosed |
| CN-114761420-A | Optimized GIP peptide analogs | 安泰博医药 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022106646-A1 | LACTAM AND LACTONE DERIVATIVES OF FORMULA (IA) FOR USE IN THE TREATMENT OF DISEASES CAUSED BY A CORONAVIRUS INFECTION AND/OR A VIRAL RESPIRATORY INFECTION | Université Catholique de Louvain (BE) | 2022-05-27 | — | — | WO | disclosed |
| EP-4000620-A1 | LACTAM AND LACTONE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION SUCH AS COVID-19 | Université catholique de Louvain (BE) | 2022-05-25 | — | — | EP | disclosed |
| US-20220073963-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING TYPE 1 DIABETES AND OTHER AUTOIMMUNE DISEASES | UNIV JOHNS HOPKINS (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590237-B2 | Pharmaceutical formulation comprising incretin-insulin conjugates | IAPP, GLP1R, INSR | TFPI 2876/4885NPY4R 92/4885NPY1R 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.